Authors
Benjamin L Handen, Ira T Lott, Bradley T Christian, Nicole Schupf, Sid OBryant, Mark Mapstone, Anne M Fagan, Joseph H Lee, Dana Tudorascu, Mei‐Cheng Wang, Elizabeth Head, William Klunk, Beau Ances, Florence Lai, Shahid Zaman, Sharon Krinsky‐McHale, Adam M Brickman, H Diana Rosas, Annie Cohen, Howard Andrews, Sigan Hartley, Wayne Silverman, Alzheimer's Biomarker Consortium‐Down Syndrome (ABC‐DS)
Publication date
2020
Source
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Volume
12
Issue
1
Pages
e12065
Description
Introduction
Adults with Down syndrome (DS) are at exceptionally high risk for Alzheimer's disease (AD), with virtually all individuals developing key neuropathological features by age 40. Identifying biomarkers of AD progression in DS can provide valuable insights into pathogenesis and suggest targets for disease modifying treatments.
Methods
We describe the development of a multi‐center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid‐based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16‐month intervals), as well as genetic modifiers of AD risk and progression.
Results
Approximately 400 individuals will be enrolled in the study (more than 370 to date). The methodological approach from the administrative, clinical, neuroimaging, omics, neuropathology, and …
Scholar articles
BL Handen, IT Lott, BT Christian, N Schupf, S OBryant… - Alzheimer's & Dementia: Diagnosis, Assessment & …, 2020